1stOncology™: Cancer Intelligence Service – Page 13346 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director

On September 3, 2019 Melinta Therapeutics, Inc. (Nasdaq: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, reported that Jennifer Sanfilippo has been named interim chief executive officer and director, effective August 28, 2019 (Press release, Cempra, SEP 3, 2019, View Source [SID1234539247]). Prior to this appointment, Ms. Sanfilippo served as senior vice president and general counsel of Melinta.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"Jennifer’s appointment to interim chief executive officer is the result of a thoughtful succession planning process undertaken by the board of directors. Jennifer is also an ideal addition to Melinta’s board of directors and we are pleased that the Board and organization will continue to benefit from her extensive leadership skills, proven track record and hands-on experience in the antibiotics sector within her new roles," said David Gill, chairman of Melinta.

"I am honored to serve as interim chief executive officer and to join Melinta’s board of directors. I look forward to working closely with the Board, management team and all of our employees as we remain focused on the Company’s strategy to best position Melinta for its next phase," said Jennifer Sanfilippo, interim chief executive officer of Melinta. "The Board and I are fully committed to ensuring a smooth transition as we continue to advance Melinta’s mission to provide both patients and physicians with potentially life-saving therapeutic solutions that address the evolving global threat of bacterial infections and antibiotic resistance."

Ms. Sanfilippo is a seasoned life sciences industry executive with demonstrated success in the areas of general management, legal and compliance. Prior to joining Melinta, Ms. Sanfilippo held a series of leadership roles at The Medicines Company, where her tenure as legal and compliance counsel provided critical support for the commercialization of The Medicine Company’s robust portfolio of antibiotics to treat serious bacterial infections. Ms. Sanfilippo holds a Bachelor of Arts degree in history, magna cum laude, from New York University and a juris doctorate from the Rutgers School of Law, where she was managing editor of the Rutgers Law Review.

Castle Biosciences Announces Time Change for Presentation at the Baird 2019 Global Healthcare Conference

On September 4, 2019 Castle Biosciences, Inc. (Nasdaq: CSTL) reported that its presentation at the Baird 2019 Global Healthcare Conference in New York City is now scheduled for 3:45 p.m. Eastern time on Wednesday, September 4, 2019 (Press release, Castle Biosciences, SEP 3, 2019, View Source [SID1234539246]).

A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at View Source A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference

On September 3, 2019 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:35 a.m. EDT on Tuesday, September 10, at the H.C. Wainwright 21st Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City (Press release, Puma Biotechnology, SEP 3, 2019, View Source [SID1234539245]).

A live webcast of the presentation will be available on the Company’s website at www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases

On September 3, 2019 Puma Biotechnology, Inc. (Nasdaq: PBYI) reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NERLYNX (neratinib) for the treatment of breast cancer patients with brain metastases (Press release, Puma Biotechnology, SEP 3, 2019, View Source [SID1234539244]).

"Receiving Orphan Drug Designation from the FDA signifies our continued progress and commitment to developing treatments for patients with HER2-positive breast cancer," said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. "Despite expanded treatment options for HER2-positive breast cancer, brain metastases in these patients represent a significant clinical challenge, as well as sources of morbidity and mortality for most of these patients. The blood-tumor penetrability of NERLYNX represents a potential treatment option for these underserved patients."

The FDA Orphan Drug Designation program grants orphan designation to investigational drugs designed to treat, prevent, or diagnose rare medical diseases or conditions that affect fewer than 200,000 individuals in the United States. Orphan designation qualifies sponsors for several key benefits and incentives, including opportunities for grant funding towards clinical trial costs, tax credits, user fee waivers, and the potential for a seven-year period of marketing exclusivity upon FDA approval of the investigational drug for the indication for which it has orphan designation.

About HER2-Positive Breast Cancer

Approximately 20 to 25 percent of breast cancer tumors over-express the HER2 protein. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery, up to 25% of patients treated with trastuzumab experience recurrence.

Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019

On September 3, 2019 Exelixis, Inc. (Nasdaq: EXEL) reported that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the Morgan Stanley 17th Annual Global Healthcare Conference, which is being held next week in New York (Press release, Exelixis, SEP 3, 2019, View Source [SID1234539243]). Exelixis’ presentation has been scheduled for Tuesday, September 10, 2019 at 4:40 PM EDT / 1:40 PM PDT.

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.